Staying Connected with ringID
RingID in a Nutshell RingID is a next-generation social media platform that merges the most popular features across the industry into one comprehensive app. With...
Profiles Of People Who Spend Six Figures A Year On Rent
Some say renting is like throwing your money away. If that’s the case, what about the people who spend six figures a year on rent?...
Seagen says CEO has resigned
Shares of Seagen Inc. were up 2.4% in trading on Monday after the company said its president and CEO Clay Siegall has resigned. Seagen had...
Griffon soars toward biggest gain in 35 years after reviewing alternatives, including possible sale
Shares of Griffon Corp. soared 23.4% toward a record in morning trading Monday, after the diversified management and holding company said it started a review...
Starbucks offers travel cost reimbursement to those seeking abortion or gender-affirming procedures
Starbucks Corp. announced Monday that it has added a worker healthcare benefit, offering travel cost reimbursement to those who are enrolled in its program and...
Walmart to pilot program aimed at putting new college grads on the path to a $210,000 salary
Walmart Inc. said Monday that it is piloting the College2Career program this summer, which will focus on putting new college grads on a career path...
New York City is ‘approaching’ a COVID alert level of ‘high’ and people should again wear face masks indoors
New York City is approaching a COVID alert level of "high," according to a statement from the health department, that urges New Yorkers to again...
Gold finishes up 0.3% Monday, snaps 2-session skid
Gold futures rose on Monday, ending a 2-session slid, as the dollar's surge took a breather and Treasury yields pulled back from a recent peak....
IQIYI stock soars after J.P. Morgan swings to bullish from bearish, quadruples price target
Shares of iQIYI Inc. soared 17.7% in afternoon trading Monday, after a double upgrade by J.P. Morgan analyst Alex Yao to buy from underweight, saying...
FDA declines to authorize fluvoxamine as a COVID-19 treatment
The Food and Drug Administration said Monday that it won't authorize fluvoxamine, a generic treatment for obsessive-compulsive disorder, as a COVID-19 therapy. "The FDA has...